View Item 

Show simple item record

Selection of Response Criteria for Clinical Trials of Sarcoma Treatment
dc.contributor.authorSchuetze, Scott M.
dc.contributor.authorBaker, Laurence H.
dc.contributor.authorBenjamin, Robert S.
dc.contributor.authorCanetta, Renzo
dc.date.accessioned2017-12-15T16:48:24Z
dc.date.available2017-12-15T16:48:24Z
dc.date.issued2008-04
dc.identifier.citationSchuetze, Scott M.; Baker, Laurence H.; Benjamin, Robert S.; Canetta, Renzo (2008). "Selection of Response Criteria for Clinical Trials of Sarcoma Treatment." The Oncologist 13: 32-40.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139995
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherSarcoma
dc.subject.otherResponse
dc.subject.otherImaging
dc.subject.otherClinical trials
dc.titleSelection of Response Criteria for Clinical Trials of Sarcoma Treatment
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USA;
dc.contributor.affiliationotherDepartment of Sarcoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA;
dc.contributor.affiliationotherBristol‐Myers Squibb, Wallingford, Connecticut, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139995/1/onco0032.pdf
dc.identifier.doi10.1634/theoncologist.13-S2-32
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceHawkins DS, Rajendran JG, Conrad EU 3rd, et al. Evaluation of chemo‐therapy response in pediatric bone sarcomas by [F‐18]‐fluorodeoxy‐Dglucose positron emission tomography. Cancer. 2002; 94: 3277 – 3284
dc.identifier.citedreferenceMarten K, Auer F, Schmidt S, et al. Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur Radiol. 2006; 16: 781 – 790
dc.identifier.citedreferenceKoh DM, Cook GJ, Husband JE, New horizons in oncologic imaging. N Engl J Med. 2003; 348: 2487 – 2488
dc.identifier.citedreferenceChoi H, Charnsangavej C, Faria C, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753 – 1759
dc.identifier.citedreferenceBenjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007; 25: 1760 – 1764
dc.identifier.citedreferenceBulusu VR, Jephcott CR, Fawcett S, et al. RECIST and Choi criteria for response assessment (RA) in patients with inoperable and metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate. Cambridge GIST study group experience. J Clin Oncol. 2007; 25 suppl 18S: 549s
dc.identifier.citedreferenceGimel P, Hubert J, Iochum S, et al. ]Contribution of the latest generation CT in preoperative assessment of kidney cancer]. Prog Urol. 2002; 12: 1310 – 1317, French
dc.identifier.citedreferenceLau D, Seibert A, Gandara D, et al. Computer‐assisted image analysis of bronchioloalveolar carcinoma. Clin Lung Cancer. 2005; 6: 281 – 286
dc.identifier.citedreferenceCastillo E, Lawler LP, Diagnostic radiology and nuclear medicine. J Surg Oncol. 2005; 92: 191 – 202
dc.identifier.citedreferenceAvril NE, Weber WA, Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am. 2005; 43: 189 – 204
dc.identifier.citedreferenceVan den Abbeele AD, The lessons of GIST—PET and PET/CT: A new paradigm for imaging. The Oncologist. 2008; 13 suppl 2: 8 – 13
dc.identifier.citedreferenceSchuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005; 103: 339 – 348
dc.identifier.citedreferenceHawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005; 23: 8828 – 8834
dc.identifier.citedreferenceEschmann SM, Friedel G, Paulsen F, et al. Repeat 18F‐FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non‐small cell lung cancer. Lung Cancer. 2007; 55: 165 – 171
dc.identifier.citedreferenceWesterterp M, Van Westreenen HL, Sloof GW, et al. Role of positron emission tomography in the (re‐)staging of oesophageal cancer. Scand J Gastroenterol Suppl. 2006; 243: 116 – 122
dc.identifier.citedreferenceNanni C, Rubello D, Castellucci P, et al. 18F‐FDG PET/CT fusion imaging in paediatric solid extracranial tumours. Biomed Pharmacother. 2006; 60: 593 – 606
dc.identifier.citedreferenceBrenner W, Bohuslavizki KH, Eary JF, PET imaging of osteosarcoma. J Nucl Med. 2003; 44: 930 – 942
dc.identifier.citedreferenceCalvo R, Marti‐Climent JM, Richter JA, et al. Three‐dimensional clinical PET in lung cancer: Validation and practical strategies. J Nucl Med. 2000; 41: 439 – 448
dc.identifier.citedreferenceFukui MB, Blodgett TM, Snyderman CH, et al. Combined PET‐CT in the head and neck: Part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics. 2005; 25: 913 – 930
dc.identifier.citedreferenceRees J, Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol. 2003; 16: 643 – 650
dc.identifier.citedreferenceRahmouni A, Luciani A, Itti E, MRI and PET in monitoring response in lymphoma. Cancer Imaging. 2005; 5: S106 – S112
dc.identifier.citedreferenceRosen MA, Schnall MD, Dynamic contrast‐enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res. 2007; 13: 770s – 776s
dc.identifier.citedreferencePreda A, Wielopolski PA, Ten Hagen TL, et al. Dynamic contrast‐enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft‐tissue sarcomas. MAGMA. 2004; 17: 296 – 302
dc.identifier.citedreferencevan Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC, et al. Dynamic contrast‐enhanced MR imaging in monitoring response to isolated limb perfusion in high‐grade soft tissue sarcoma: Initial results. Eur Radiol. 2003; 13: 1849 – 1858
dc.identifier.citedreferenceFahn W, Issels RD, Emerging treatments for soft tissue sarcoma of adults. Expert Opin Emerg Drugs. 2004; 9: 313 – 334
dc.identifier.citedreferenceBorden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: State of the translational science. Clin Cancer Res. 2003; 9: 1941 – 1956
dc.identifier.citedreferenceMilano A, Apice G, Ferrari E, et al. New emerging drugs in soft tissue sarcoma. Crit Rev Oncol Hematol. 2006; 59: 74 – 84
dc.identifier.citedreferenceGollob JA, Bonomi P, Historic evidence and future directions in clinical trial therapy of solid tumors. Oncology (Williston Park). 2006; 20 suppl 5: 10 – 18
dc.identifier.citedreferenceTannock IF, Some problems related to the design and analysis of clinical trials. Int J Radiat Oncol Biol Phys. 1992; 22: 881 – 885
dc.identifier.citedreferenceNational Cancer Institute. Understanding the Approval Process for New Cancer Treatments, Accessed June 1, 2007, Available at http://www.cancer.gov/clinicaltrials/learning/approval‐process‐for‐cancer‐drugs/page5.
dc.identifier.citedreferencePhan A, Patel S, Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol. 2003; 4: 433 – 439
dc.identifier.citedreferenceRubinstein LV, Therapeutic studies. Hematol Oncol Clin North Am. 2000; 14: 849 – 876, ix
dc.identifier.citedreferenceU.S. Food and Drug Administration. ASCO/FDA Lung Cancer Endpoints Workshop. 2003, 4, 15, Accessed June 1, 2007, Available at http://www.fda.gov/cder/drug/cancer_endpoints/lungFinalSummary.doc.
dc.identifier.citedreferenceScott J, McGettigan G, Regulatory approvals for oncology products based on accelerated clinical development and limited data packages‐2. Regulatory Rapporteur. 2005, 7/8, 6 – 15
dc.identifier.citedreferenceGlynne‐Jones R, Mawdsley S, Pearce T, et al. Alternative clinical end points in rectal cancer—are we getting closer?. Ann Oncol. 2006; 17: 1239 – 1248
dc.identifier.citedreferenceTherasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205 – 216
dc.identifier.citedreferenceMiller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981; 47: 207 – 214
dc.identifier.citedreferenceWHO Handbook for Reporting Results of Cancer Treatment, Geneva, Switzerland: World Health Organization, 1979, 1 – 45.
dc.identifier.citedreferenceTsuchida Y, Therasse P, Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol. 2001; 37: 1 – 3
dc.identifier.citedreferenceMcHugh K, Kao S, Response evaluation criteria in solid tumours (RECIST): Problems and need for modifications in paediatric oncology?. Br J Radiol. 2003; 76: 433 – 436
dc.identifier.citedreferenceGehan EA, Tefft MC, Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?. J Natl Cancer Inst. 2000; 92: 179 – 181
dc.identifier.citedreferenceTherasse P, Eisenhauer EA, Verweij J, RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer. 2006; 42: 1031 – 1039
dc.identifier.citedreferencevan Klaveren RJ, Aerts JG, de Bruin H, et al. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer. 2004; 43: 63 – 69
dc.identifier.citedreferenceTropine A, Dellani PD, Glaser M, et al. Differentiation of fibroblastic meningiomas from other benign subtypes using diffusion tensor imaging. J Magn Reson Imaging. 2007; 25: 703 – 708
dc.identifier.citedreferenceChong S, Lee KS, Chung MJ, et al. Neuroendocrine tumors of the lung: Clinical, pathologic, and imaging findings. Radiographics. 2006; 26: 41 – 57, discussion 57–58
dc.identifier.citedreferenceMiller TR, Pinkus E, Dehdashti F, et al. Improved prognostic value of 18F‐FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med. 2003; 44: 192 – 197
dc.identifier.citedreferenceTrillet‐Lenoir V, Freyer G, Kaemmerlen P, et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: Accuracy of the RECIST criteria. Br J Radiol. 2002; 75: 903 – 908
dc.identifier.citedreferenceBond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children’s Oncology Group study. Pediatr Blood Cancer. 2007, 1, 29, [Epub ahead of print]
dc.identifier.citedreferenceMazumdar M, Smith A, Schwartz LH, A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol. 2004; 57: 358 – 365
dc.identifier.citedreferenceKelloff GJ, Sullivan DM, Wilson W, et al. FDG‐PET Lymphoma Demonstration Project Invitational Workshop. Acad Radiol. 2007; 14: 330 – 339
dc.identifier.citedreferenceChoi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004; 183: 1619 – 1628
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0032.pdf
Size:
5.225MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.